ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "gastrointestinal complications"

  • Abstract Number: 2368 • 2019 ACR/ARP Annual Meeting

    Risk of Diverticulitis and Gastro-Intestinal Perforation in Rheumatoid Arthritis Treated with Tocilizumab Compared to Rituximab and Abatacept: A Prospective Propensity-matched Cohort Study

    Claire Rempenault1, Cédric Lukas 1, Bernard Combe 2, Isabelle Pane 3, Xavier Mariette 4, Jacques-Eric Gottenberg 5 and Jacques Morel 1, 1Department of Rheumatology, Montpellier University Hospital, Montpellier, France, Montpellier, Languedoc-Roussillon, France, 2CHU Montpellier, Montpellier University, Montpellier, France, 3Centre de Recherche en Epidémiologie et Statistiques, INSERM U1153, Centre d'Épidémiologie Clinique, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris (AP-HP), Descartes University, Paris, France., Paris, Ile-de-France, France, 4Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, 5Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France

    Background/Purpose: Several studies have reported an increased risk of gastro-intestinal perforation (GIP) in rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ) compared to conventional synthetic…
  • Abstract Number: 1105 • 2018 ACR/ARHP Annual Meeting

    Abatacept Is Effective in Experimental Digestive and Lung Tissue Fibrosis

    Gonçalo Boleto1, Christophe Guignabert2, Sonia Pezet3, Anne Cauvet3, Jérémy Sadoine4, Ly Tu2, Carole Nicco3, Camille Gobeaux5, Frederic Batteux3, Yannick Allanore3 and Jérôme Avouac1, 1Université Paris Descartes, Sorbonne Paris Cité, Service de Rhumatologie A, Hôpital Cochin, Paris, France, Paris, France, 2INSERM UMR_S 999, Le Plessis-Robinson, France, Le Plessis-Robinson, France, 3Université Paris Descartes, Sorbonne Paris Cité, INSERM U1016, Institut Cochin, CNRS UMR8104, Paris, France, Paris, France, 4EA 2496 Pathologie, Imagerie et Biothérapies Orofaciales, UFR Odontologie, Université Paris Descartes and PIDV, PRES Sorbonne Paris Cité, Montrouge, France, Montrouge, France, 5Clinical Chemistry Laboratory, Cochin and Hôtel-Dieu Hospitals, Paris, France, Paris, France

    Background/Purpose: A previous report showed that abatacept (IgG-CTLA-4) prevented and induced regression of inflammation-driven dermal fibrosis in two different mouse models of systemic sclerosis (SSc)…
  • Abstract Number: 1725 • 2018 ACR/ARHP Annual Meeting

    Fecal Microbiota Transplantation in Patients with Systemic Sclerosis- a Pilot Study

    Håvard Fretheim1, Oyvind Midtvedt1, Anders Heiervang Tennøe1, Henriette Didriksen1, Torhild Garen1, Espen Bækkevold1, Johannes R. Hov1, Knut EA Lundin2, Marius Trøseid1, Øyvind Molberg1 and Anna-Maria Hoffmann-Vold1, 1Oslo University Hospital, Oslo, Norway, 2Dept of gastroenterology, Oslo University Hospital, Oslo, Norway

    Background/Purpose: Up to 90% of patients with systemic sclerosis (SSc) have symptoms from the gastrointestinal (GI) tract. Earlier studies have shown a distinct alteration of…
  • Abstract Number: 1739 • 2018 ACR/ARHP Annual Meeting

    What Do Patient Reported Outcomes for Routine Monitoring of Gastrointestinal Tract Symptoms in a Systemic Sclerosis Center Tell Us about Clinical Features of Potential Small Intestinal Bacterial Overgrowth?

    Jessica Zhu1, Craig Gale2, Joshua Biber3, Mandana Nikpour4, Murray Baron5 and Tracy M. Frech6, 1School of Medicine, University of Utah, Salt Lake City, UT, 2Bioinformatics, University of Utah, Salt Lake City, UT, 3University of Utah, Salt Lake City, UT, 4The University of Melbourne, Melbourne, Australia, Melbourne, Australia, 5Department of Medicine, McGill University, Montreal, QC, Canada, 6Division of Rheumatology, University of Utah, Salt Lake City, UT

    Background/Purpose: The implementation of patient reported outcome measures (PROMs) is increasingly recognized as a critical aspect of clinical practice.  The use of gastrointestinal (GI) PROMs…
  • Abstract Number: 1767 • 2018 ACR/ARHP Annual Meeting

    Occurrence and Etiology of Gastrointestinal Perforation in Patients with Vasculitis

    Vanessa L. Kronzer1, Daniel Larson2, Cynthia S. Crowson3,4, Kenneth J. Warrington5, Steven R. Ytterberg5, Ashima Makol4 and Matthew J. Koster4, 1Internal Medicine, Mayo Clinic, Rochester, MN, 2Pathology, Mayo Clinic, Rochester, MN, 3Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 4Rheumatology, Mayo Clinic, Rochester, MN, 5Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN

    Background/Purpose: This study aimed to characterize the presenting features and outcomes of patients with small- or medium-vessel vasculitis and gastrointestinal perforation. Methods: Using a retrospective…
  • Abstract Number: 2604 • 2018 ACR/ARHP Annual Meeting

    Incidence of Serious Gastrointestinal Events and Inflammatory Bowel Disease Among Tildrakizumab-Treated Patients with Moderate to Severe Plaque Psoriasis: Data from 3 Large Randomized Clinical Trials

    Melinda Gooderham1, Boni E. Elewski2, David M. Pariser3, Howard Sofen4, Alan M Mendelsohn5, Nicole Cichanowitz6 and Qing Li6, 1Probity Medical Research, and Skin Center for Dermatololgy, Waterloo, and Peterborough, ON, Canada, 2University of Alabama at Birmingham, Birmingham, AL, 3Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, 4Ronald Reagan UCLA Medical Center, Department of Medicine (Dermatology) UCLA, Los Angeles, CA, 5Sun Pharmaceutical Industries, Inc., Princeton, NJ, 6Merck & Co., Inc., Kenilworth, NJ

    Background/Purpose: Tildrakizumab (TIL), a high-affinity, humanized, immunoglobulin G1κ, anti–interleukin-23p19 monoclonal antibody, has demonstrated efficacy in the treatment of chronic plaque psoriasis.1,2 Here, we evaluate the…
  • Abstract Number: 2936 • 2018 ACR/ARHP Annual Meeting

    Esophageal Erosion Predicts Progression of Lung Disease in Patients with Systemic Sclerosis

    Silvia Laura Bosello1, Enrico De Lorenzis1, Gerlando Natalello2, Giovanni Battista Canestrari1, Laura Gigante1, Lucrezia Verardi1, Ludovica Berardini3 and Elisa Gremese1, 1Division of Rheumatology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, 2Division of Rhematology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, 3Division of Respiratory Medicine, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy

    Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in Systemic Sclerosis (SSc) but its pathogenesis is not fully understood. Esophageal disease is…
  • Abstract Number: 2939 • 2018 ACR/ARHP Annual Meeting

    Clinical Features Associated with Severe Lower Bowel Involvement in Systemic Sclerosis

    Eric Dein1, Laura K. Hummers2, Christopher A. Mecoli3,4 and Zsuzsanna McMahan5, 1Department of Internal Medicine, Johns Hopkins Bayview, Baltimore, MD, 2Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, 3Internal Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, 4Rheumatology, Johns Hopkins University, Baltimore, MD, 5Department of Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Although up to 90% of scleroderma (SSc) patients are affected by gastrointestinal (GI) dysmotility, clinical features of patients with severe lower gastrointestinal involvement are…
  • Abstract Number: 728 • 2017 ACR/ARHP Annual Meeting

    Symptoms of Autonomic Dysfunction in Systemic Sclerosis Assessed By the Compass-31 Questionnaire

    Brittany Adler1, James Russell2, Laura K. Hummers3 and Zsuzsanna McMahan4, 1Rheumatology, Johns Hopkins University, Baltimore, MD, 2Neurology, Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, 3Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, 4Department of Internal Medicine, Johns Hopkins University, Baltimore, MD

    Background/Purpose: Autonomic dysfunction is a known complication of systemic sclerosis (SSc) and can affect vascular tone, gastrointestinal (GI) motility, and heart rate and blood pressure…
  • Abstract Number: 1248 • 2017 ACR/ARHP Annual Meeting

    Evaluation of Validated Patient Reported Outcome Measures to Assess Sensitivity to Change in Patients with Systemic Sclerosis and Gastroesophageal Reflux Disease —a Scleroderma Clinical Trials Consortium Collaborative Project

    Zsuzsanna McMahan1, Tracy M. Frech2, David Lim3, Veronica J. Berrocal4, Cosimo Bruni5, Marco Matucci-Cerinic6, Vanessa Smith7, Karin Melsons8, Susanna Proudman9, Jinyu Zhang10, Fabian A Mendoza11, Melanie Woods3 and Dinesh Khanna3, 1Department of Internal Medicine, Johns Hopkins University, Baltimore, MD, 2Division of Rheumatology, University of Utah, Salt Lake City, UT, 3University of Michigan, Ann Arbor, MI, 4Div of Rheumatology, University of Michigan, Ann Arbor, MI, 5Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy, 6Dept of Medicine/Div of Rheum, University of Florence, Firenze, Italy, 7Faculty of Internal Medicine, Ghent University, Ghent, Belgium, 8Ghent University, Gent, Belgium, 9Discipline of Medicine, University of Adelaide, Adelaide, Australia, 10Thomas Jefferson University, Philadelphia, PA, 11Jefferson Institute of Molecular Medicine and Scleroderma Center, Rheumatology Division, Department of Medicine, Thomas Jefferson University, Philadelphia, PA

    Background/Purpose: The UCLA SCTC GIT 2.0 and NIH PROMIS GI Symptoms Scales are validated in scleroderma to assess patient-reported gastrointestinal (GI) involvement. We sought to…
  • Abstract Number: 2668 • 2017 ACR/ARHP Annual Meeting

    Responsiveness of University of California Los Angeles Scleroderma Clinical Trial Consortium (GIT2.0) and Intestinal Visual Analogue Scale to Change in Systemic Sclerosis Patients

    Yossra A Suliman1, Suzanne Kafaja2, Mohamed Alemam3, yasser Shaweesh4, Kasra Tavakoli5 and Daniel E. Furst6, 1Rheumatology and Rehabilitation dept., Rheumatology and Rehabilitation dept. Assiut university hospital, Assiut Egypt, Assiut, Egypt, 2Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, 3Clinical Pathology and Laboratory Medicine Department, Assistant Lecturer, Qena, Egypt, 4John H. Stroger Jr. Hospital of cook county, chicago, IL, 5Department of medicine, university of California Los Angeles, Los Angeles, CA, 6David Geffen School of Medicine at UCLA, Los Angeles, CA

    Background/Purpose: Gastrointestinal tract (GIT) involvement in systemic sclerosis (SSc) is the most common internal organ involvement. Among the few validated patient-reported outcome measures for GI…
  • Abstract Number: 2898 • 2016 ACR/ARHP Annual Meeting

    Anti-Reflux Medications in Diffuse Cutaneous Systemic Sclerosis:  Is Empiric Use of Proton Pump Inhibitors Supported?

    Tracy M. Frech1, Ami A. Shah2, Monique Hinchcliff3, Flavia V. Castelino4, Shervin Assassi5, Elana J. Bernstein6, Robyn T. Domsic7, Jessica K. Gordon8, Victoria K. Shanmugam9,10, Virginia D. Steen11, Maureen Murtaugh12, Bernie LaSalle13, Dinesh Khanna14 and Faye N. Hant15, 1Division of Rheumatology, University of Utah, Salt Lake City, UT, 2Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, 4Rheumatology, Allergy, Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 5Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, 6Department of Medicine, Division of Rheumatology, Columbia University, New York, NY, 7Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 8Rheumatology, Hospital for Special Surgery, New York, NY, 9Rheumatology, George Washington University, Great Falls, VA, 10Division of Rheumatology, The George Washington University, Washington, DC, 11Rheumatology, Georgetown University Medical Center, Washington, DC, 12University of Utah, Salt Lake, UT, 13University of Utah, Salt Lake City, UT, 14University of Michigan, Ann Arbor, MI, 15Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Table 1: PRESS
  • Abstract Number: 2902 • 2016 ACR/ARHP Annual Meeting

    Preliminary Evaluation of Gastroesophageal Reflex Disease Outcome Measures in Scleroderma– Scleroderma Clinical Trials Consortium Gastrointestinal Working Group

    Zsuzsanna McMahan1, Tracy M. Frech2, Guya Piemonte3, Marco Matucci-Cerinic4, Susanna Proudman5,6, Veronica J. Berrocal7, Ron Hays8 and Dinesh Khanna9, 1Department of Internal Medicine, Johns Hopkins University, Baltimore, MD, 2Division of Rheumatology, University of Utah, Salt Lake City, UT, 3University of Florence, Florence, Italy, 4Department of Medicine, Division of Rheumatology, University of Florence, Florence, Italy, 5Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, 6Discipline of Medicine, University of Adelaide, Adelaide, Australia, 7Div of Rheumatology, University of Michigan, Ann Arbor, MI, 8UCLA, Los Angeles, CA, 9University of Michigan, Ann Arbor, MI

    Background/Purpose: Gastrointestinal tract (GIT) involvement occurs in approximately 95% of patients with systemic sclerosis (SSc). There is consensus in the Scleroderma Clinical Trials Consortium (SCTC)…
  • Abstract Number: 2911 • 2016 ACR/ARHP Annual Meeting

    A Comparison of Gastrointestinal Disease Severity in African American and Caucasian Scleroderma Patients

    Carolyn Fridley1 and Virginia D. Steen2, 1Rheumatology, Georgetown University, Washington, DC, 2Rheumatology, Georgetown University Medical Center, Washington, DC

    A Comparison of Gastrointestinal Disease Severity in African American and Caucasian Scleroderma Patients Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease. After skin involvement…
  • Abstract Number: 827 • 2016 ACR/ARHP Annual Meeting

    Severe Gastrointestinal Disease in Early Systemic Sclerosis Is Associated with an Increased Risk of Mortality

    Nicolas Richard1, Marie Hudson2, Mianbo Wang3, Murray Baron4, Genevieve Gyger1 and Canadian Scleroderma Research Group, 1McGill University, Jewish General Hospital, Montreal, QC, Canada, 2Medicine/Rheumatology, Jewish General Hospital, Lady Davis Research Institute, Montreal, QC, Canada, 3Lady Davis Institute for Medical Research, Montreal, QC, Canada, 4Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada

    Background/Purpose: Studies of severe gastrointestinal (GI) disease in systemic sclerosis (SSc) are limited by small, selected samples composed largely of subjects with prevalent disease. We…
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology